Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2024-06-21 Major Shareholding Noti…
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including major shareholding notifications and changes in special relationships (e.g., director resignations, share disposals). This document type is specifically used to report significant changes in shareholding thresholds and ownership structure, which aligns with the 'Major Shareholding Notification' category.
2024-06-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a specific individual (Kim Byung-chul, CEO) in Clinomics. This is a standard regulatory filing for insider trading/director dealings, which corresponds to the 'Director's Dealing' category.
2024-06-17 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official report of the results of an Extraordinary General Meeting (EGM) held on 2024-06-14. It details the voting outcomes for various agenda items, including the amendment of articles of incorporation, the appointment of directors, and the appointment of auditors. This falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2024-06-14 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment of an outside director (사외이사). This falls under the category of board or management changes, specifically the appointment of a director, which is classified as MANG (Board/Management Information).
2024-06-14 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal 'Notice of Convocation of Extraordinary General Meeting' (주주총회소집결의) filed by Clinomics. It details the agenda for an upcoming meeting, including the appointment of directors, auditors, and changes to business objectives. This is a standard regulatory filing for shareholder meetings, which falls under the Proxy Solicitation & Information Statement category as it provides the necessary information for shareholders to vote on the proposed agenda items.
2024-05-30 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice of Extraordinary General Meeting of Shareholders' (주주총회소집공고) for Clinomics Co., Ltd. It includes the meeting date, location, agenda items (such as changes to the articles of incorporation, appointment of directors and auditors), and information regarding proxy voting and electronic voting procedures. This document is a standard proxy solicitation material sent to shareholders to inform them of an upcoming meeting and request their participation/votes. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2024-05-30 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.